PCDHB5

Across TCGA pan-cancer cohorts, PCDHB5 Mutation is linked to patient survival in 11 of 34 cancer types, making it a survival-associated PCDHB5 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher PCDHB5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHB5 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCS, UCEC, and ACC are the cancer types where PCDHB5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	OS	Median	All	0.131	0.710	<.001	36	view →
UCEC	DFS	Median	All	0.942	0.607	.002	28	view →
ACC	DFS	Median	All	0.120	0.772	<.001	27	view →
LUAD	DFS	Median	IV	0.045	0.717	<.001	17	view →
STAD	DFS	Median	III,IV	0.681	0.314	.028	12	view →
OV	DFS	Median	III,IV	0.140	0.532	.002	6	view →
LIHC	OS	Median	All	0.098	0.774	.001	6	view →
LUSC	OS	Median	All	0.197	0.528	.004	4	view →
GBM	DFS	Median	All	0.066	0.242	.042	3	view →
COAD	OS	Median	III,IV	0.208	0.791	.008	3	view →
SKCM	DFS	Median	III,IV	0.312	0.556	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 11 strongest of 11 lineages.

PCDHB5–UCS (OS)

Open the UCS breakdown →